Global Resistance of Imipenem/Relebactam Against Gram-Negative Bacilli: Systematic Review and Meta-Analysis

Overview

Journal Curr Ther Res Clin Exp

Specialty Pharmacology

Date 2024 Jan 4

PMID 38174096

Authors

Reza Abniki

Amirhossein Tashakor

Melika Masoudi

Davood Mansury

Affiliations

Soon will be listed here.

Abstract

Background: Relebactam, previously known as MK-7655, is currently being tested in combination with imipenem as a class A and class C β-lactamase inhibitor, including KPC from .

Objective: The objective of the current study was to evaluate the activity of imipenem/relebactam against gram-negative bacilli.

Methods: After applying exclusion and inclusion criteria, 72 articles with full texts that describe the prevalence of imipenem/relebactam resistance were chosen for the meta-analysis and systematic review. Articles published between January 2015 and February 2023 were surveyed. The systematic literature search was conducted in PubMed, Web of Science, Google Scholar, and Scopus.

Results: The pooled estimation of 282,621 sample isolates revealed that the prevalence rate of imipenem/relebactam resistance is roughly 14.6% (95% CI, 0.116%-0.182%).

Conclusions: The findings of this analysis show that imipenem/relebactam resistance is rare in the majority of developed countries. Given that relebactam has proven to restore the activity of imipenem against current clinical isolates, further research into imipenem/relebactam is necessary.

Citing Articles

Recombinase-aided amplification assay for rapid detection of imipenem-resistant and rifampin-resistant .

Zhou Y, Shi R, Mu L, Tian L, Zhou M, Lyu W Front Cell Infect Microbiol. 2024; 14:1428827.

PMID: 39318475 PMC: 11420161. DOI: 10.3389/fcimb.2024.1428827.

Novel Antibiotics for Gram-Negative Nosocomial Pneumonia.

Almyroudi M, Chang A, Andrianopoulos I, Papathanakos G, Mehta R, Paramythiotou E Antibiotics (Basel). 2024; 13(7).

PMID: 39061311 PMC: 11273951. DOI: 10.3390/antibiotics13070629.

References

Karlowsky J, Lob S, Kazmierczak K, Hawser S, Magnet S, Young K . In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme. J Antimicrob Chemother. 2018; 73(7):1872-1879. DOI: 10.1093/jac/dky107. View

Papp-Wallace K, Barnes M, Alsop J, Taracila M, Bethel C, Becka S . Relebactam Is a Potent Inhibitor of the KPC-2 β-Lactamase and Restores Imipenem Susceptibility in KPC-Producing Enterobacteriaceae. Antimicrob Agents Chemother. 2018; 62(6). PMC: 5971601. DOI: 10.1128/AAC.00174-18. View

Bail L, Ito C, Arend L, Nogueira K, Tuon F . Activity of imipenem-relebactam and ceftolozane-tazobactam against carbapenem-resistant Pseudomonas aeruginosa and KPC-producing Enterobacterales. Diagn Microbiol Infect Dis. 2021; 102(1):115568. DOI: 10.1016/j.diagmicrobio.2021.115568. View

Logan L, Weinstein R . The Epidemiology of Carbapenem-Resistant Enterobacteriaceae: The Impact and Evolution of a Global Menace. J Infect Dis. 2017; 215(suppl_1):S28-S36. PMC: 5853342. DOI: 10.1093/infdis/jiw282. View

Onguru P, Erbay A, Bodur H, Baran G, Akinci E, Balaban N . Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections. J Korean Med Sci. 2009; 23(6):982-7. PMC: 2610663. DOI: 10.3346/jkms.2008.23.6.982. View

Mushtaq S, Meunier D, Vickers A, Woodford N, Livermore D . Activity of imipenem/relebactam against Pseudomonas aeruginosa producing ESBLs and carbapenemases. J Antimicrob Chemother. 2020; 76(2):434-442. DOI: 10.1093/jac/dkaa456. View

Sahra S, Jahangir A, Hamadi R, Jahangir A, Glaser A . Clinical and Microbiologic Efficacy and Safety of Imipenem/Cilastatin/Relebactam in Complicated Infections: A Meta-analysis. Infect Chemother. 2021; 53(2):271-283. PMC: 8258290. DOI: 10.3947/ic.2021.0051. View

Hernandez-Garcia M, Garcia-Castillo M, Bou G, Cercenado E, Delgado-Valverde M, Oliver A . Imipenem-Relebactam Susceptibility in Isolates Recovered from ICU Patients from Spain and Portugal (SUPERIOR and STEP Studies). Microbiol Spectr. 2022; 10(5):e0292722. PMC: 9602286. DOI: 10.1128/spectrum.02927-22. View

Perrin A, Larsonneur E, Nicholson A, Edwards D, Gundlach K, Whitney A . Evolutionary dynamics and genomic features of the Elizabethkingia anophelis 2015 to 2016 Wisconsin outbreak strain. Nat Commun. 2017; 8:15483. PMC: 5458099. DOI: 10.1038/ncomms15483. View

10.

Rebold N, Morrisette T, Lagnf A, Alosaimy S, Holger D, Barber K . Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections. Open Forum Infect Dis. 2021; 8(12):ofab554. PMC: 8661073. DOI: 10.1093/ofid/ofab554. View

11.

Simner P, Beisken S, Bergman Y, Posch A, Cosgrove S, Tamma P . Cefiderocol Activity Against Clinical Isolates Exhibiting Ceftolozane-Tazobactam Resistance. Open Forum Infect Dis. 2021; 8(7):ofab311. PMC: 8275882. DOI: 10.1093/ofid/ofab311. View

12.

Bhagwat S, Hariharan P, Joshi P, Palwe S, Shrivastava R, Patel M . Activity of cefepime/zidebactam against MDR Escherichia coli isolates harbouring a novel mechanism of resistance based on four-amino-acid inserts in PBP3. J Antimicrob Chemother. 2020; 75(12):3563-3567. DOI: 10.1093/jac/dkaa353. View

13.

Gomis-Font M, Cabot G, Lopez-Arguello S, Zamorano L, Juan C, Moya B . Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones. J Antimicrob Chemother. 2022; 77(4):957-968. DOI: 10.1093/jac/dkab496. View

14.

Lob S, Hackel M, Kazmierczak K, Young K, Motyl M, Karlowsky J . Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program). Antimicrob Agents Chemother. 2017; 61(6). PMC: 5444184. DOI: 10.1128/AAC.02209-16. View

15.

Karlowsky J, Lob S, Kazmierczak K, Young K, Motyl M, Sahm D . Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program. Antimicrob Agents Chemother. 2018; 62(7). PMC: 6021649. DOI: 10.1128/AAC.00169-18. View

16.

Zhang H, Gontjes K, Han J, Alby K, Lapp Z, Snitkin E . Characterization of resistance to newer antimicrobials among carbapenem-resistant in the post-acute-care setting. Infect Control Hosp Epidemiol. 2022; 44(7):1159-1162. PMC: 9883590. DOI: 10.1017/ice.2022.185. View

17.

Lin J, Lai C, Yang C, Huang Y, Lin H . Clinical manifestations, molecular characteristics, antimicrobial susceptibility patterns and contributions of target gene mutation to fluoroquinolone resistance in Elizabethkingia anophelis. J Antimicrob Chemother. 2018; 73(9):2497-2502. DOI: 10.1093/jac/dky197. View

18.

Karlowsky J, Lob S, Raddatz J, DePestel D, Young K, Motyl M . In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United.... Clin Infect Dis. 2020; 72(12):2112-2120. DOI: 10.1093/cid/ciaa381. View

19.

Johnston B, Thuras P, Porter S, Anacker M, VonBank B, Vagnone P . Activity of Imipenem-Relebactam against Carbapenem-Resistant Escherichia coli Isolates from the United States in Relation to Clonal Background, Resistance Genes, Coresistance, and Region. Antimicrob Agents Chemother. 2020; 64(5). PMC: 7179611. DOI: 10.1128/AAC.02408-19. View

20.

Rolston K, Gerges B, Reitzel R, Shelburne S, Aitken S, Raad I . In vitro activity of imipenem/releactam and comparator agents against clinical bacterial isolates from patients with cancer. J Glob Antimicrob Resist. 2022; 29:1-6. DOI: 10.1016/j.jgar.2022.01.020. View